SAN JOSE, Calif. — For the past 11 weeks, prosecutors revealed emails from desperate investors. They held up falsified documents side by side with the originals. They called dozens of witnesses who lobbed accusations of deceit and evasiveness.And on Friday, the person whom prosecutors have been making their case against — Elizabeth Holmes, the founder of the failed blood testing start-up Theranos — took the stand to defend herself. She faces 11 counts of defrauding investors over Theranos’s technology and business in a case that has been billed as a referendum on Silicon Valley’s start-up culture. She has pleaded not guilty.Ms. Holmes — whose rise and fall captivated the public and who has been held up as a symbol of the tech industry’s hubris and the last decade’s culture of grift — began her testimony by answering a series of questions about Theranos. She delved into her background and how she began the Silicon Valley start-up, which had promised to revolutionize health care by using just a drop of …
Latest Business News
Orchestrating Value in Global Tourism and Hospitality (2/13/2026) - Orchestrating Value in Global Tourism and Hospitality The global tourism… Read more...
The Algorithmic Ocean: Structural Transformation and Artificial Intelligence Industrialization in the Global Cruise Sector (2/12/2026) - Algorithmic Waters: The Strategic Integration of AI in the Global… Read more...
AI’s New Horizon in the Travel Industry (2/12/2026) - AI's New Horizon in the Travel Industry The global travel… Read more...
AI and Technology Innovation Reshaping U.S. Tourism and Hospitality (1/30/2026) - AI and Technology Innovation Reshaping U.S. Tourism and HospitalityThe U.S.… Read more...
AI and Technology Innovation Reshaping Global E-Commerce in 2026 (1/30/2026) - AI and Technology Innovation Reshaping Global E-Commerce in 2026E-commerce has… Read more...
The Architecture of Autonomous Commerce (1/25/2026) - The Architecture of Autonomous Commerce - Strategic Evolution of AI… Read more...
Intelligent Capital: The Scenario Based Outlook for 2026 (1/25/2026) - Intelligent Capital Outlook 2026 The Scenario Based Outlook for 2026… Read more...
Unlocking Hidden Value: A New Secondary Market for Late Stage Rare Disease Therapies (1/19/2026) - Unlocking Hidden Value A New Secondary Market for Late Stage… Read more...